Consequently, combined treatment with tamoxifen and GRP78 inhibition in in vivo models of ER+ breast cancer not only restored tamoxifen sensitivity but also increased macrophage infiltration and lipid peroxidation, demonstrating the therapeutic potential of targeting GRP78 in endocrine-resistant breast tumors [319,320]. Here, ESR1 is linked to breast carcinoma.